News
-
-
Kriya Selected for FDA PreCheck Pilot Program
-
Kriya Announces Presentations at ASGCT 2026 Highlighting Advances Across Gene Therapy Platform
-
Kriya Appoints Sachiyo Minegishi as Chief Financial Officer
-
Kriya appoints Greg Di Russo, MD as Chief Medical Officer
-
Kriya Announces $320 Million Series D Financing to Advance Pipeline of Gene Therapies for Chronic Diseases of High Unmet Need
-
Kriya Presents Data at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
-
Kriya Announces Thirteen Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2025
-
Kriya Announces Publication of Preclinical Data for its Investigational AAV-FGF21 Gene Therapy Demonstrating Durable Reversal of Liver Fibrosis
-
Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene Therapy Product Candidate for Thyroid Eye Disease (TED), at ESOPRS Annual Meeting
Disclaimer
Kriya’s durable medicines are investigational and have not been approved as safe or effective by any regulatory health authority.